Source: China – South China Morning PostBiotech firm Insilico Medicine, backed by the Hong Kong Investment Corporation (HKIC), is building a “digital Einstein” to revolutionise how scientists discover new medicines, and plans to continue expanding its research base in China to stay ahead of global rivals after its Hong Kong listing on Tuesday.
“Biotechnology is a high-risk field like a ‘molecular casino’,” said founder Alex Zhavoronkov. “Even with artificial intelligence, you can lose 90 per cent of the time.”
The 11-year-old company…Read More